Child and adult immunisation

The National Immunisation Program (NIP) is a series of immunisations given at specific times throughout a person’s life from birth through to adulthood. State and territory health departments also fund some additional vaccines. The Queensland Government via Metro North Health works with registered vaccine service providers to protect the community against vaccine preventable infectious diseases. 

The Metro North Public Health Unit (PHU) can provide clinical advice regarding immunisation including registration of a service provider, ordering and cold chain management and catch-up schedules. The Metro North PHU can be contacted by phone on 07 3624 1111 or email via qhip-admin@health.qld.gov.au

If you are a suitably qualified service and would like to discuss registering as a service provider to access vaccines as part of the National Immunisation Program, please email qhip-admin@health.qld.gov.au.

Queensland Adult Immunisation Services (QASIS)

Vaccination advice for people over 16 years of age with complex medical conditions as well as those who have experienced, or are at risk of, an adverse event following immunisations. For more information including referral guidelines, please visit Queensland Adult Specialist Immunisation Service (QASIS) - Royal Brisbane and Women's Hospital

Infant and maternal vaccination for RSV

The Queensland Paediatric Respiratory Syncytial Virus Prevention Program is expanding from 1 December 2024. This expanded program provides free Respiratory Syncytial Virus (RSV) immunisation to eligible Queensland infants and pregnant people.

From 1 December 2024, the program will offer infants protection against severe RSV disease through infant immunisation and maternal vaccination.

The products funded under this program are:

• Abrysvo ®, an RSV vaccine given to pregnant people between 28 and 36 weeks of pregnancy to protect infants against severe RSV disease from birth for up to 6 months.
• Nirsevimab (brand name Beyfortus®), a long-acting monoclonal antibody that provides infants and young children protection against severe RSV disease for at least 5 months from administration.

Both products have been determined by the Therapeutic Goods Administration (TGA) to be safe and effective and are approved for use in Australia.

Infants and pregnant people who are residents of Queensland can receive free RSV immunisation under this program. Eligibility for this program is not linked to Medicare status.

Infants born to a person who received RSV vaccination during their pregnancy do not routinely require Nirsevimab. Please view the clinical guidance for immunisation service providers or visit the Queensland Government website for more information including eligibility criteria and consent forms.

QHIP registered providers will be able to offer Abrysvo ® to pregnant people from 1 December 2024. This includes providers in general practice, pharmacy, Aboriginal and Torres Strait Islander health services, community immunisation clinics and some maternity and antenatal health services. 

Nirsevimab 50mg continues to be available, 100mg stock is expected to be available in early 2025.

Abrysvo ® can be ordered from Queensland Health Immunisation Program (QHIP) from 25 November 2024. QHIP registered providers can place an order for Nirsevmab and Abrysvo ® in their next routine order using the vaccine order form or by emailing QHIP-Admin@health.qld.gov.au.

Stock of  Abrysvo ® from QHIP is only for maternal vaccination only. For all other indications, please order through your usual private wholesalers.

Meningococcal ACWY vaccines

From 1 July 2024, there are changes to the meningococcal ACWY vaccines under the National Immunisation Program (NIP). Key points include:  

• From 1 July 2024, the NIP will fund meningococcal ACWY vaccine MenQuadfi® for adolescents aged 14 to 16 years and those aged 15 to 19 years on catch-up schedules. Children aged 12 months and people with specified medical conditions will continue to receive Nimenrix®. 
• Vaccines will be delivered through school vaccination programs and health services, including pharmacies, for those young people on catch-up schedules. 
• It is mandatory to report all meningococcal ACWY vaccines you have administered to the Australian Immunisation Register (AIR). 

Further information will be available on the Department of Health and Aged Care's website when the change takes effect on 1 July 2024. For more information, please visit the program advice fact sheet or the meningococcal ACWY vaccine website. 

Queensland MenB Vaccination Program

The Queensland MenB Vaccination Program will provide free meningococcal B (menB) vaccines to eligible Queensland infants, children and adolescents. This program will be implemented in full by the end of March 2024, with vaccine deliveries to Queensland Health registered vaccination service providers commencing from mid-February 2024. For more information, please visit the Queensland Health website.

NIP Shingles Program from 1 November 2023

From 1 November 2023, there are changes to the shingles vaccination schedule under the National Immunisation Program (NIP). 

Key points 

• From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the NIP schedule. The groups eligible to receive the free vaccine will also change. The NIP will fund a 2-dose course for eligible people. 

• Shingrix® is a non-live vaccine. It’s highly effective in the prevention of herpes zoster (shingles) and its complications, including post-herpetic neuralgia (PHN), in both immunocompetent and immunocompromised people.

The NIP has released a factsheet for vaccination providers for further program information.